Literature DB >> 25584031

Effect of tamoxifen on ovarian reserve: A randomized controlled assessor-blind trial in a mouse model.

Ayşe Topçu Akduman1, Kemal Özerkan1, Berrin Zik2, Sabire Peker2, Berrin Avcı3, Barış Ata4.   

Abstract

OBJECTIVE: To determine whether tamoxifen (TMX) exposure causes a permanent decrease in ovarian reserve.
MATERIAL AND METHODS: A randomized controlled assessor-blind trial including 30 adult female inbred BALB/C mice. Fifteen mice in the TMX group were given a single 0.1-mg dose of TMX intraperitoneally. Fifteen mice in the control group were given a single dose of the vehicle at the same volume intraperitoneally. Two cycles later, blood samples were collected for determination of anti-Müllerian hormone (AMH) levels, and the mice were sacrificed. After gonadectomy, ovarian size was measured, and follicles were counted under light microscopy.
RESULTS: Median serum AMH levels were 6.53 and 6.14 ng/ml in the control and TMX groups, respectively (p=0.03). Ovarian size was significantly decreased in the TMX group. While the number of primordial (9 vs 8), primary (6 vs 3), and secondary (4.5 vs 5) follicles were similar, there were significantly fewer preantral (11.5 vs 6, p<0.01) and antral (2 vs 1, p: 0.03) follicles, as well as corpora lutea (6 vs 3, p: 0.04), in the TMX group than in the control group. The number of atretic (2.5 vs 5, p: 0.048) follicles was increased in the TMX group.
CONCLUSION: Tamoxifen administration leads to arrested growth of gonadotropin-sensitive follicles, while insensitive follicles can remain unaffected. TMX is merely an endocrine disruptor, and it does not cause a decrease in primordial follicle pool.

Entities:  

Keywords:  Tamoxifen; anti-Müllerian hormone; antral follicle count; folliculogenesis; ovarian reserve

Year:  2014        PMID: 25584031      PMCID: PMC4285211          DOI: 10.5152/jtgga.2014.14166

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  19 in total

1.  Regulation of cytochrome P450 aromatase messenger ribonucleic acid and activity by steroids and gonadotropins in rat granulosa cells.

Authors:  S L Fitzpatrick; J S Richards
Journal:  Endocrinology       Date:  1991-09       Impact factor: 4.736

2.  Fourteen-day oral combination dose toxicity study of CGS 16949 A (aromatase inhibitor) with 5-fluorouracil or tamoxifen in rats.

Authors:  A Matsuda; K Higuchi; M Karasawa; S Yoneyama; J Deguchi; M Miyamoto
Journal:  J Toxicol Sci       Date:  1997-02       Impact factor: 2.196

3.  Estrogen receptor-beta is critical to granulosa cell differentiation and the ovulatory response to gonadotropins.

Authors:  John F Couse; Mariana M Yates; Bonnie J Deroo; Kenneth S Korach
Journal:  Endocrinology       Date:  2005-04-14       Impact factor: 4.736

4.  Estrogens enhance the adenosine 3',5'-monophosphate-mediated induction of follicle-stimulating hormone and luteinizing hormone receptors in rat granulosa cells.

Authors:  M Knecht; J M Darbon; T Ranta; A J Baukal; K J Catt
Journal:  Endocrinology       Date:  1984-07       Impact factor: 4.736

5.  Effects of partial versus pure antiestrogens on ovulation and the pituitary-ovarian axis in the rat.

Authors:  J Donath; Y Nishino
Journal:  J Steroid Biochem Mol Biol       Date:  1998-08       Impact factor: 4.292

6.  Autocrine role of estrogens in the augmentation of luteinizing hormone receptor formation in cultured rat granulosa cells.

Authors:  B Kessel; Y X Liu; X C Jia; A J Hsueh
Journal:  Biol Reprod       Date:  1985-06       Impact factor: 4.285

7.  Estrogens augment the stimulation of ovarian aromatase activity by follicle-stimulating hormone in cultured rat granulosa cells.

Authors:  E Y Adashi; A J Hsueh
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

8.  Proliferating cell nuclear antigen marks the initiation of follicular growth in the rat.

Authors:  K Oktay; R S Schenken; J F Nelson
Journal:  Biol Reprod       Date:  1995-08       Impact factor: 4.285

9.  Recent trends in breast cancer among younger women in the United States.

Authors:  Louise A Brinton; Mark E Sherman; J Daniel Carreon; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

10.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more
  1 in total

1.  Impact of tamoxifen therapy on fertility in breast cancer survivors.

Authors:  Lisa M Shandley; Jessica B Spencer; Amy Fothergill; Ann C Mertens; Amita Manatunga; Elisavet Paplomata; Penelope P Howards
Journal:  Fertil Steril       Date:  2016-11-22       Impact factor: 7.329

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.